Skip to content

Trial · Interventional

RecruitingPhase 4Registry data

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

NCTNCT07247084 (opens ClinicalTrials.gov in a new tab)Other id27331Other idI8F-MC-GPJF
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Recruiting
Phase
Phase 4
Enrollment
3,000 participants (estimated)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Open label (no masking)
Countries
1 country

United Kingdom

Start
24 Nov 2025
Primary completion
Jul 2029 (estimated)
Completion
Jul 2032 (estimated)
First posted
25 Nov 2025
Last update posted
9 Sept 2026
Conditions
Obesity

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2026202820302032
  1. Ph 4

    A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

    NCT07247084

    24 Nov 2025 to est. Jul 2032

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Eligible participants must be registered patients at a participating site. Participation in the study will last about 260 weeks.

Interventions

  • TirzepatideDrug
  • Standard of CareOther

Arms2

  • Experimental

    Tirzepatide + Standard of Care

    Participants will receive tirzepatide subcutaneously (SC) + standard of care

  • Active comparator

    Standard of Care

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Percent Change from Baseline in Body Weight

    Time frame · Baseline, 24 months

Secondary outcomes(16)

  1. Time from Baseline to Onset of Type 2 Diabetes

    Time frame · Baseline through 60 months

  2. Percentage of Participants Converting from Prediabetes to Normoglycemia

    Time frame · 60 months

  3. Percentage of Participants with Normoglycemia at Baseline who Develop Prediabetes

    Time frame · 60 months

  4. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame · Baseline, 60 months

  5. Percentage of Participants who Develop a New Obesity-Related Complication

    Time frame · 60 months

  6. Change from Baseline in Waist Circumference

    Time frame · Baseline, 60 months

  7. Change from Baseline in Waist-to-Height Ratio

    Time frame · Baseline, 60 months

  8. Change from Baseline in Total Cholesterol

    Time frame · Baseline, 60 months

  9. Change from Baseline in Systolic Blood Pressure

    Time frame · Baseline, 60 months

  10. Change from Baseline in Diastolic Blood Pressure

    Time frame · Baseline, 60 months

  11. Percent Change from Baseline Urinary Albumin-to-Creatinine Ratio (UACR)

    Time frame · Baseline, 60 months

  12. Change from Baseline in EQ-5D-5L

    Time frame · Baseline, 60 months

  13. Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-lite-CT)

    Time frame · Baseline, 60 months

  14. Change from Baseline in Healthcare Resource Utilization (HCRU)

    Time frame · Baseline, 60 months

  15. Change from Baseline in Alanine Aminotransferase (ALT)

    Time frame · Baseline, 60 months

  16. Change from Baseline in Aspartate Aminotransferase (AST)

    Time frame · Baseline, 60 months

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

More studies

1 study on this page

PubMed tag: none · 2026

SURMOUNT-REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity.

Rutter et al. 2026Obesity (Silver Spring, Md.)

PMID 42297568DOI 10.1002/oby.70247PUB-42297568

Full text at the publisher
Publisher page

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by \>0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity) Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other types of diabetes * Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening

PepBank is a research reference. Talk to a doctor before you use any peptide.